

China bets high on COVID-19 mRNA vaccines

November 30, 2021 | News

GenScript ProBio, Abogen Biosciences and Walvax Biotechnology enter into collaboration



GenScript ProBio, Suzhou Abogen Biosciences Technology Co. and Walvax Biotechnology Co. have announced a collaboration on commercial manufacturing of a mRNA vaccine project (ABO-028M). Walvax Biotechnology will submit a biologics license application (BLA) of ABO-028M project and GenScript ProBio will provide exclusive services for the commercial manufacturing of plasmids in the project.

In June 2020, the COVID-19 mRNA vaccine project that Abogen Biosciences engaged with the Academy of Military Medical Sciences (AMMS) of the PLA Academy of Military Science and Walvax Biotechnology successfully obtained the NMPA clinical trial approval. It was one of the first batch of mRNA vaccine projects approved by government of China.

GenScript ProBio, with the advantage of plasmid GMP manufacturing platform and rich experiences in plasmid clinical manufacturing, contributed to accelerate the pace of the mRNA vaccine project into clinical trial.

The project is currently undergoing international multicenter clinical trials and has obtained Phase III clinical trial approvals from the medical products regulatory authorities of Mexico, Indonesia and Nepal. In September 2021, Walvax Biotechnology's modular facilities for COVID-19 mRNA vaccine was put into operation to accelerate the industrial manufacturing of COVID-19 vaccine.